Ezogabine, a drug that opens up the KCNQ2/3 type potassium channel, significantly improved symptoms of depression and anhedonia.
Ezogabine, an antiepileptic drug, reduces the excitability of cortical and spinal motor neurons associated with ALS.
Ezogabine, an FDA approved anti-convulsant, appears to significantly reduce symptoms in those with major depressive disorder.
A new study reports an anti-epilepsy drug could reduce the debilitating impact of strokes.